Joan Merrill to Interferon Type I
This is a "connection" page, showing publications Joan Merrill has written about Interferon Type I.
Connection Strength
0.650
-
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
Score: 0.195
-
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
Score: 0.140
-
Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013 Jun; 43:78-84.
Score: 0.105
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
Score: 0.093
-
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010; 2010.
Score: 0.087
-
Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
Score: 0.030